EPCAM and cancer: Taken together, the combination of the abovementioned information (i.e., the numbers of low- or non-EpCAM-expression CTC subtypes and CTC clusters) is regarded as a feasible direction to improve the performance of current CTC counting in terms of CTC detection rate [21,114] and prediction accuracy of cancer patient outcomes [114].